The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma

The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma

We focused on the therapeutic effect of pembrolizumab for metastatic urothelial carcinoma (mUC) and evaluated predictive factors for improving clinical outcomes. We conducted a retrospective multicenter cohort study of patients with mUC who received pembrolizumab. The endpoint was to evaluate the as...

Full description

Bibliographic Details
Main Authors: Risa Tomioka-Inagawa, Keita Nakane, Torai Enomoto, Masayuki Tomioka, Tomoki Taniguchi, Takashi Ishida, Kaori Ozawa, Kimiaki Takagi, Hiroki Ito, Shinichi Takeuchi, Makoto Kawase, Kota Kawase, Daiki Kato, Manabu Takai, Koji Iinuma, Shigeaki Yokoi, Masahiro Nakano, Takuya Koie
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biomedicines
Subjects:
multicenter cohort study
oncological outcomes
pembrolizumab
metastatic urothelial carcinoma
neutrophil-to-lymphocyte ratio
Online Access:https://www.mdpi.com/2227-9059/10/7/1609

Internet

https://www.mdpi.com/2227-9059/10/7/1609

Similar Items